Literature DB >> 8770923

The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes.

B J Stith1, M L Goalstone, R Espinoza, C Mossel, D Roberts, N Wiernsperger.   

Abstract

Although metformin is an important antidiabetic, its mechanism of action is still unknown. To study its mechanism, we examined metformin stimulation of insulin action on the Xenopus oocyte. Similar to therapeutic concentrations, maximal stimulation of insulin-induced meiotic cell division was achieved at about 1-10 microg/ml (or 7.7-77 /microM) metformin. An equivalent concentration of metformin was required to elevate receptor tyrosine kinase activity (in whole cells or a membrane-cortex preparation) and, through this tyrosine kinase activation, inositol 1,4,5-trisphosphate (IP3) production. With whole cells, the preincubation time for metformin stimulation of insulin action (approximately 1 h) was equivalent to the time required for metformin to maximize tyrosine phosphorylation and raise IP3, levels. With the membrane-cortex preparation, metformin was active within minutes; thus, metformin may act at an intracellular site. Since metformin can increase IP3, mass, we prevented elevation of calcium by prior microinjection of a calcium chelator or heparin (a drug that inhibits IP3 binding to the IP3 receptor). Both the chelator and heparin blocked metformin stimulation of insulin action on whole cells. Since microinjection of IP3, also stimulates insulin action, metformin may stimulate insulin action by elevation of intracellular calcium in addition to activation of the receptor tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770923     DOI: 10.1210/endo.137.7.8770923

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin.

Authors:  P R Pryor; S C Liu; A E Clark; J Yang; G D Holman; D Tosh
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 2.  Insulin resistance and improvements in signal transduction.

Authors:  Nicolas Musi; Laurie J Goodyear
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 3.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 4.  Phospholipase C and D regulation of Src, calcium release and membrane fusion during Xenopus laevis development.

Authors:  Bradley J Stith
Journal:  Dev Biol       Date:  2015-03-05       Impact factor: 3.582

Review 5.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

Authors:  N F Wiernsperger; C J Bailey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

7.  Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.

Authors:  Inmaculada García-Ruiz; Pablo Solís-Muñoz; Erica Gómez-Izquierdo; María Teresa Muñoz-Yagüe; Angela M Valverde; José A Solís-Herruzo
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

Review 8.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Therapeutic Concentrations of Metformin: A Systematic Review.

Authors:  Farshad Kajbaf; Marc E De Broe; Jean-Daniel Lalau
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

10.  Activation of Src and release of intracellular calcium by phosphatidic acid during Xenopus laevis fertilization.

Authors:  Ryan C Bates; Colby P Fees; William L Holland; Courtney C Winger; Khulan Batbayar; Rachel Ancar; Todd Bergren; Douglas Petcoff; Bradley J Stith
Journal:  Dev Biol       Date:  2013-11-21       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.